Title: MACROCYCLIC COMPOUNDS, POLYMERS, AND METHODS FOR MAKING SAME

Abstract: The application relates to macrocyclic compounds and related polymers, as well as to processes for synthesizing them, e.g., using olefins as starting material.
MACROCYCLIC COMPOUNDS, POLYMERS, AND METHODS FOR MAKING SAME

RELATED APPLICATIONS

[01] This application claims priority to, and the benefit of, U.S. provisional application Nos. 61/994,545, filed May 16, 2014 and 62/024,776, filed July 15, 2014. The entire contents of each of these provisional applications are incorporated herein by reference in their entireties.

BACKGROUND

[02] Macrocyclic compounds have found use as biologically active compounds with commercial applications ranging from antibiotics to olfactory active compounds, specifically musks. Many approaches to the synthesis of macrocyclic compounds, and specifically macro lactones, have been developed, including coupled polymerization and depolymerization of polyesters, and ring expansion of cyclic ketones (see, e.g., US 2,020,298, DE 2,026,056, and EP 0,841,333). Reviews of macrolactonization approaches can be found in, e.g., Synthesis 1999, 10, 1707-1723 and Molecules 2013, 18, 6230-6268.

[03] New macrolactonization approaches that allow for the use of different starting materials and the incorporation of new functional groups are desired.

SUMMARY

[04] In one aspect, the application features a compound according to Formula I or Formula II:
or a salt thereof, wherein,

R¹ is a bond, optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;

R² is optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;

X is O or NR³;

R⁴ is hydrogen or optionally substituted C₁-C₁₂ alkyl;

Z is hydrogen or ;

one of the ----- is a double bond and the other ----- is a single bond;

m is an integer between 1 and 10; and

n is an integer between 1 and 100,000.

In another aspect, the application features a method of producing a compound of Formula I and/or Formula II, a salt thereof, or a combination thereof. The method includes reacting a compound of Formula III or Formula IV:

with a compound of Formula V:
to obtain a reaction mixture comprising a compound of Formula I or Formula II, a salt thereof, or a combination thereof:

Formula I, or

Formula II,

wherein,

R¹ is a bond, optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;

R² is optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;

R³ is hydrogen, optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;

R⁴ is hydrogen, optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;

X is O or NR⁵;

R⁵ is hydrogen or optionally substituted C₁-C₁₂ alkyl;

Z is hydrogen or

one of the ——— is a double bond and the other ——— is a single bond;
m is an integer between 1 and 10; and
n is an integer between 1 and 100,000.

[06] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. In the specification, the singular forms also include the plural unless the context clearly dictates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present application, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative only and are not intended to be limiting.

[07] Other features and advantages of the application will be apparent from the following detailed description and claims.

**BRIEF DESCRIPTION OF THE DRAWINGS**

Figure 1 is a \(^1\)H NMR spectrum of 8,12,12-trimethyl-1,5-dioxacyclododecan-6-one.
Figure 2 is a \(^1\)H NMR spectrum of poly(7-(3-hydroxypropoxy)-3,7-dimethyloctanoic acid).
Figure 3 is a \(^1\)H NMR spectrum of 7,11,11-trimethyl-1,4-dioxacycloundecan-5-one.
Figure 4 is a \(^1\)H NMR spectrum of poly(7-(2-hydroxyethoxy)-3,7-dimethyloctanoic acid).

**DETAILED DESCRIPTION**

[08] In one aspect, the application features a compound according to Formula I or Formula II:
or a salt thereof, wherein,
R¹ is a bond, optionally substituted C₁₋C₁₂ alkyl, optionally substituted C₂₋C₁₂ alkenyl, or optionally substituted C₂₋C₁₂ alkynyl;
R² is optionally substituted C₁₋C₁₂ alkyl, optionally substituted C₂₋C₁₂ alkenyl, or optionally substituted C₂₋C₁₂ alkynyl;
X is O or NR²;
R⁴ is hydrogen or optionally substituted C₁₋C₁₂ alkyl;

\[
\text{Z is hydrogen or } \quad ;
\]

one of the ----- is a double bond and the other ----- is a single bond;
m is an integer between 1 and 10; and
n is an integer between 1 and 100,000.

[09] In some embodiments, the compound is a compound according to Formula I.
[10] In some embodiments, the compound is a compound according to Formula II.
[11] In some embodiments, the number of atoms comprising the ring structure of Formula I is between 10 and 30.
[12] In some embodiments, the number of atoms comprising the ring structure of Formula I is between 13 and 19.
[13] In some embodiments, the number of atoms comprising the ring structure of Formula I is greater than 30.
[14] In embodiments, the number of atoms comprising the ring structure of Formula I does not include exocyclic atoms such as an oxygen atom attached to a ring-forming carbon atom of a carbonyl group.
[15] In some embodiments, X is O.
[16] In some embodiments, X is NR².
[17] In some embodiments, X is NH.

[18] In some embodiments, Z is hydrogen.

[19] In some embodiments, Z is

[20] In some embodiments, each $R^1$ independently is optionally substituted linear C$_{1-12}$ alkyl or branched C$_{3-12}$ alkyl.

[21] In some embodiments, each $R^1$ independently is unsubstituted linear C$_{1-12}$ alkyl or branched C$_{3-12}$ alkyl.

[22] In some embodiments, each $R^1$ independently is unsubstituted linear C$_{1-12}$ alkyl.

[23] In some embodiments, each $R^1$ independently is unsubstituted branched C$_{3-12}$ alkyl.

[24] In some embodiments, each $R^1$ independently is optionally substituted linear C$_{2-12}$ alkenyl or branched C$_{3-12}$ alkenyl.

[25] In some embodiments, each $R^1$ independently is unsubstituted linear C$_{2-12}$ alkenyl or branched C$_{3-12}$ alkenyl.

[26] In some embodiments, each $R^1$ independently is unsubstituted linear C$_{2-12}$ alkenyl.

[27] In some embodiments, each $R^1$ independently is unsubstituted branched C$_{3-12}$ alkenyl.

[28] In some embodiments, each $R^2$ independently is optionally substituted linear or branched C$_{3-12}$ alkyl.

[29] In some embodiments, each $R^2$ independently is linear C$_{1-12}$ alkyl or branched C$_{3-12}$ alkyl substituted with one or more hydroxyl groups.

[30] In some embodiments, each $R^2$ independently is unsubstituted linear C$_{1-12}$ alkyl or branched C$_{3-12}$ alkyl.

[31] In some embodiments, each $R^2$ independently is unsubstituted linear C$_{1-12}$ alkyl.
[32] In some embodiments, each $R^2$ independently is unsubstituted branched $C_3$-$C_{12}$ alkyl.

[33] In some embodiments, each $R^2$ independently is optionally substituted linear $C_2$-$C_{12}$ alkenyl or branched $C_3$-$C_{12}$ alkenyl.

[34] In some embodiments, each $R^2$ independently is unsubstituted linear $C_2$-$C_{12}$ alkenyl or branched $C_3$-$C_{12}$ alkenyl.

[35] In some embodiments, each $R^2$ independently is unsubstituted linear $C_2$-$C_{12}$ alkenyl.

[36] In some embodiments, each $R^2$ independently is unsubstituted branched $C_3$-$C_{12}$ alkenyl.

[37] In some embodiments, each $R^2$ independently is optionally substituted linear $C_2$-$C_{12}$ alkynyl or branched $C_4$-$C_{12}$ alkynyl.

[38] In some embodiments, each $R^2$ independently is unsubstituted linear $C_2$-$C_{12}$ alkynyl or branched $C_4$-$C_{12}$ alkynyl.

[39] In some embodiments, each $R^2$ independently is unsubstituted linear $C_2$-$C_{12}$ alkynyl.

[40] In some embodiments, each $R^2$ independently is unsubstituted branched $C_4$-$C_{12}$ alkynyl.

[41] In some embodiments, the compound of Formula II is selected from those listed in Table 2 and salts thereof.

[42] In some embodiments, the compound of Formula I is selected from those listed in Table 3 and salts thereof.

[43] In some embodiments, $n$ is greater than 1 (e.g., between 2 and about 100, between about 100 and about 1,000, between about 1,000 and about 5,000, between about 5,000 and about 10,000, between about 10,000 and about 50,000, between about 50,000 and about 100,000, between about 10 and about 100,000, between about 100 and about 10,000, between about 200 and about 20,000, or between about 500 and about 50,000).

[44] In some embodiments, the compound of Formula II has a molecular weight of about 5000 Da or greater.

[45] In some embodiments, $m$ is 1 or 2.
[46] In some embodiments, \( m \) is 3, 4, 5, 6, 7, 8, 9, or 10.

[47] In another aspect, the application features a method of producing a compound of Formula I and/or Formula II, or a salt, or a combination thereof, comprising reacting a compound of Formula III or Formula IV:

\[
\text{O} \quad \text{R}^1 \quad \text{O} \quad \text{R}^3
\]

**Formula III,** or

\[
\text{R}^4 \quad \text{O} \quad \text{R}^1 \quad \text{O} \quad \text{R}^3
\]

**Formula IV,**

with a compound of Formula V:

\[
\text{HO} \quad \text{R}^2 \quad \text{OH}
\]

**Formula V,**

to obtain a reaction mixture comprising a compound of Formula I or Formula II, a salt thereof, or a combination thereof:

\[
\text{R}^1 \quad \text{O} \quad \text{R}^2
\]

**Formula I,** or

\[
\text{Z} \quad \text{R}^2 \quad \text{O} \quad \text{R}^1 \quad \text{O} \quad \text{R}^2 \quad \text{O} \quad \text{Z}
\]

**Formula II,**

wherein,
R¹ is a bond, optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;
R² is optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;
R³ is hydrogen, optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;
R⁴ is hydrogen, optionally substituted C₁-C₁₂ alkyl, optionally substituted C₂-C₁₂ alkenyl, or optionally substituted C₂-C₁₂ alkynyl;
X is O or NR⁵;
R⁶ is hydrogen or optionally substituted C₁-C₁₂ alkyl;
\[
\begin{align*}
\text{Z is hydrogen or} \quad & \\
\text{one of the } & \text{ is a double bond and the other } \text{ is a single bond;}
\end{align*}
\]
\[m \text{ is an integer between } 1 \text{ and } 10; \text{ and}
\][n \text{ is an integer between } 1 \text{ and } 100,000.]

[48] In some embodiments, the reaction of a compound of Formula III or Formula IV with a compound of Formula V comprises an esterification step, an etherification step, a first distillation step, and a second distillation step.

[49] In some embodiments, water is removed from the reaction mixture during the esterification step.

[50] In some embodiments, the method further comprises an amidation step, wherein a compound of Formula I, wherein X is O, reacts with NH₃ under an elevated pressure to obtain a corresponding compound of Formula I wherein X is NH.

[51] In some embodiments, the ratio of the compound of Formula III or Formula IV to the compound of Formula V is 2 to 1 or greater (e.g., about 3 to 1, 4 to 1, 5 to 1, 6 to 1, 8 to 1, or 10 to 1).

[52] In some embodiments, the esterification step is performed at a first temperature that is greater than room temperature.

[53] In some embodiments, the first temperature is about 130 °C.
[54] In some embodiments, the esterification step is performed at a first pH value that is less than or equal to 7.

[55] In some embodiments, the first pH value is less than 7.

[56] In some embodiments, the esterification step is performed for less than 4 hours.

[57] In some embodiments, the esterification step is performed for about 4 hours.

[58] In some embodiments, the esterification step is performed for greater than 4 hours (e.g., about 5-24 hours).

[59] In some embodiments, the etherification step is performed at a second temperature that is lower than the first temperature.

[60] In some embodiments, the second temperature is about 65 °C.

[61] In some embodiments, the etherification step is performed at a second pH value that is greater than or equal to the first pH.

[62] In some embodiments, the second pH value of the etherification step is greater than or equal to 7.

[63] In some embodiments, the etherification step is quenched with a base, e.g., Na₂CO₃.

[64] In some embodiments, the etherification step is quenched with Na₂CO₃, such that the pH of the reaction mixture is about 8.

[65] In some embodiments, the etherification step is performed for less than 48 hours.

[66] In some embodiments, the etherification step is performed for about 48 hours.

[67] In some embodiments, the etherification step is performed for greater than 48 hours (e.g., about 50-120 hours).

[68] In some embodiments, the first distillation step is performed to remove the compound of Formula V from the reaction mixture.

[69] In some embodiments, the compound of Formula I is separated from the compound of Formula II by performing a second distillation step.

[70] In some embodiments, each of the first and second distillation steps is independently performed at a third temperature that is between about 25 °C and about 280 °C (e.g., about 25-270 °C, 25-260 °C, 30-120 °C, 30-150 °C, 30-200 °C, 100-150 °C, 150-270 °C, or about 200-270 °C).
In some embodiments, each of the first and second distillation steps is independently performed at a pressure between 0.01 mbar and 10 mbar, (e.g., between 0.05 mbar and 5 mbar, between 0.1 mbar and 3 mbar, between 0.1 and 0.3 mbar, between 0.3 and 0.5 mbar, between 0.5 and 1.0 mbar, or between 1.0 and 1.6 mbar).

In some embodiments, the first distillation step is performed at a temperature from 25 °C to 260 °C (e.g., from 25 °C to 250 °C) under a pressure of 0.5-2.0 mbar (e.g., 0.5-1.0 mbar or 1.0-1.6 mbar).

In some embodiments, the second distillation step is performed at a temperature at 200-270 °C (e.g., 200-260 °C) under a pressure of 0.5-1.0 mbar (e.g., 0.1-0.5 mbar or 0.3-0.5 mbar).

In some embodiments, R³ is hydrogen.

In some embodiments, R³ is optionally substituted linear C₁₋C₁₂ alkyl or branched C₃₋C₁₂ alkyl.

In some embodiments, R³ is unsubstituted linear C₁₋C₁₂ alkyl or branched C₃₋C₁₂ alkyl.

In some embodiments, R³ is unsubstituted linear C₁₋C₁₂ alkyl.

In some embodiments, R³ is unsubstituted branched C₃₋C₁₂ alkyl.

In some embodiments, R⁴ is hydrogen.

In some embodiments, R⁴ is optionally substituted linear C₁₋C₁₂ alkyl or branched C₃₋C₁₂ alkyl.

In some embodiments, R⁴ is unsubstituted linear C₁₋C₁₂ alkyl or branched C₃₋C₁₂ alkyl.

In some embodiments, R⁴ is unsubstituted linear C₁₋C₁₂ alkyl.

In some embodiments, R⁴ is unsubstituted branched C₃₋C₁₂ alkyl.

In addition to making the macrocyclic compounds of Formula I, the process described herein may be used to generate the polymers of Formula II. Such polymers can be used for a variety of application, including cosmetics, coatings, medical devices, and time-release formulations, as well as any other appropriate polymer applications. These new polymers can contain either alternating ether/ester linkages, or ether/amide linkages.
The polymers described herein (of Formula II) can be used as precursors to produce macrocyclic compounds (of Formula I) that contain an ether linkage. As an example, and as illustrated in Scheme 1 below, polymers can be formed by esterifying and etherifying an olefinic acid and/or ester (e.g., compound 1a or 1b in Scheme 1) with a suitable diol of the type described in Scheme 1 (e.g., compound 2) under suitable conditions (e.g., acidic conditions; e.g., elevated temperatures; e.g., reaction times ranging from hours to days). The resulting monomer (e.g., compound 3) can then be polymerized to form a polymer (e.g., compound 5) (e.g., under vacuum distillation conditions) in the presence of a suitable catalyst, such as a basic catalyst (e.g., potassium carbonate, sodium carbonate, magnesium oxide, or basic alumina). The extent to which the diol (compound 2) is removed from the reaction mixture can influence the polymerization reaction. In one embodiment, the amount of diol (compound 2) removed from the reaction mixture (e.g., by distillation) is inversely proportional to the average molecular weight of the polymer product. The macrocyclic compound (e.g., compound 4) can be separated from the reaction mixture (e.g., by distillation) upon depolymerization/lactonization of the polymer (compound 5), which occurs via the intramolecular esterification of a terminal hydroxyl group with an internal ester group. The resulting polymer (compound 5) is a new type of ester/ether polymer, and the resulting macrocyclic compound (compound 4) is a new type of ester/ether macrocycle. The variables in Scheme 1 below, such as $R_1^1$, $R_2^2$, X, Z, etc. are as defined in Formulae I-V above.
[86] In some embodiments, an esterification procedure may occur before, concurrently with, or after an etherification procedure. In some embodiments, polymerization and/or lactonization reactions may occur during a first and/or second distillation procedure. In some embodiments, a compound of Formula II (e.g., compound 5 in Scheme 1) may be isolated from the reaction mixture in a first or a second distillation procedure. In some embodiments, a compound of Formula I wherein X is O (e.g., compound 4 in Scheme 1) may be reacted with pressurized ammonia to produce a corresponding compound of Formula I wherein X is NH (e.g., compound 6 in Scheme 1).

[87] In some embodiments, 2,6-dimethyl-6-methoxyheptanoic acid is combined with 1,6-hexanediol and methanesulfonic acid in an organic solvent (e.g., toluene) and heated, to 25 °C – 200 °C (e.g., to 25 °C, e.g., to 50 °C, e.g., to 75 °C, e.g., to 100 °C, e.g., to 110 °C, e.g., to 120 °C, e.g., to 130 °C, e.g., to 140 °C, e.g., to 150 °C, e.g., to 160 °C, e.g., to 180 °C, e.g., to 200 °C), for 0.5 – 10 hours (e.g., 0.5 hours, e.g., 1 hour, e.g., 2 hours, e.g., 3 hours, e.g., 4 hours, e.g., 5 hours, e.g., 6 hours, e.g., 8 hours, e.g., 10 hours) to perform the esterification step. The reaction is then cooled, to 25 °C – 100
°C (e.g., to 20-30 °C, e.g., to 30-40 °C, e.g., to 40-50 °C, e.g., to 50-60 °C, e.g., to 60-70 °C, e.g., to 70-80 °C, e.g., to 80-90 °C, e.g., to 90-100 °C) and additional 1,6-hexanediol is added to the reaction mixture to perform the etherification step. The reaction is kept stirring at the cooled temperature for, 1 hour – 4 days (e.g., 1 hour, e.g., 6 hours, e.g., 12 hours, e.g., 1 day, e.g., 2 days, e.g., 3 days, e.g., 4 days) before quenching the reaction with a basic aqueous solution (e.g., 10 wt.% Na₂CO₃) until the pH of the reaction mixture is slightly basic (e.g., pH = 8). A polar organic solvent (e.g., ethyl acetate) is added to reaction mixture and the phases are separated. The organic phase is washed with brine and then dried with a drying agent (e.g., Na₂SO₄). The drying agent is removed by filtration, and the organic phase solvent is subsequently removed by evaporation, yielding a residue. An inorganic catalyst (e.g., MgO) and quenching agent (e.g., Na₂CO₃) are added to the residue, and fractional distillation (the first distillation) is performed. After removing a majority of the light fraction, the macrolactone product is removed from the remaining reaction mixture by distillation (the second distillation). The macrolactone product may be further purified (e.g., by flash column chromatography). Residue in the reaction vessel after distillation includes polymer (e.g., poly(6-((6-hydroxyhexyl)oxy)-2,6-dimethylheptanoic acid)). Product compositions and yields are determined by, e.g., NMR.

[88] In some embodiments, citronellic acid is combined with 1,6-hexanediol and methanesulfonic acid in an organic solvent (e.g., toluene) and heated, to 25 °C – 200 °C (e.g., to 25 °C, e.g., to 50 °C, e.g., to 75 °C, e.g., to 100 °C, e.g., to 110 °C, e.g., to 120 °C, e.g., to 130 °C, e.g., to 140 °C, e.g., to 150 °C, e.g., to 160 °C, e.g., to 180 °C, e.g., to 200 °C), for 0.5 – 10 hours (e.g., 0.5 hours, e.g., 1 hour, e.g., 2 hours, e.g., 3 hours, e.g., 4 hours, e.g., 5 hours, e.g., 6 hours, e.g., 8 hours, e.g., 10 hours) to perform the esterification step. The reaction is then cooled, to 25 °C – 100 °C (e.g., to 20-30 °C, e.g., to 30-40 °C, e.g., to 40-50 °C, e.g., to 50-60 °C, e.g., to 60-70 °C, e.g., to 70-80 °C, e.g., to 80-90 °C, e.g., to 90-100 °C) and additional 1,6-hexanediol is added to the reaction mixture to perform the etherification step. The reaction is kept stirring at the cooled temperature for, 1 hour to 4 days (e.g., 1 hour, e.g., 6 hours, e.g., 12 hours, e.g., 1 day, e.g., 2 days, e.g., 3 days, e.g., 4 days) before quenching the reaction with a basic aqueous solution (e.g., 10 wt.% Na₂CO₃) until the pH of the reaction mixture is slightly
basic (e.g., pH = 8). A polar organic solvent (e.g., ethyl acetate) is added to reaction mixture and the phases are separated. The organic phase is washed with brine and then dried with a drying agent (e.g., Na₂SO₄). The drying agent is removed by filtration, and the organic phase solvent is subsequently removed by evaporation, yielding a residue. An inorganic catalyst (e.g., MgO) and quenching agent (e.g., Na₂CO₃) are added to the residue, and fractional distillation is performed (the first distillation). After removing a majority of the light fraction, the macrolactone product is removed from the remaining reaction mixture by distillation (the second distillation). The macrolactone product may be further purified (e.g., by flash column chromatography). Residue in the reaction vessel after distillation includes polymer (e.g., poly(11,15,15-trimethyl-1,8-dioxacyclopentadecan-9-one)). Product compositions and yields are determined by e.g., NMR.

[89] In some embodiments, citronellic acid is combined with 1,3-propanediol and methanesulfonic acid in an organic solvent (e.g., toluene) and heated, to 25 °C – 200 °C (e.g., to 25 °C, e.g., to 50 °C, e.g., to 75 °C, e.g., to 100 °C, e.g., to 110 °C, e.g., to 120 °C, e.g., to 130 °C, e.g., to 140 °C, e.g., to 150 °C, e.g., to 160 °C, e.g., to 180 °C, e.g., to 200 °C) for 0.5 – 10 hours (e.g., 0.5 hours, e.g., 1 hour, e.g., 2 hours, e.g., 3 hours, e.g., 4 hours, e.g., 5 hours, e.g., 6 hours, e.g., 8 hours, e.g., 10 hours), during which water is removed from the reaction, to perform the esterification step. The reaction is then cooled, to 25 °C – 100 °C (e.g., to 20-30 °C, e.g., to 30-40 °C, e.g., to 40-50 °C, e.g., to 50-60 °C, e.g., to 60-70 °C, e.g., to 70-80 °C, e.g., to 80-90 °C, e.g., to 90-100 °C) and left stirring, for 1 hour – 4 days (e.g., 1 hour, e.g., 6 hours, e.g., 12 hours, e.g., 1 day, e.g., 2 days, e.g., 3 days, e.g., 4 days), to perform the etherification step, before quenching the reaction with a basic aqueous solution (e.g., 10% Na₂CO₃) until the pH of the reaction mixture is slightly basic (e.g., pH = 8). A polar organic solvent (e.g., ethyl acetate) is added to reaction mixture and the phases are separated. The organic phase is washed with brine and then dried with a drying agent (e.g., Na₂SO₄). The drying agent is removed by filtration and the solvent is removed by evaporation, yielding a residue. An inorganic catalyst (e.g., MgO) and quenching agent (e.g., Na₂CO₃) are added to the residue, and fractional distillation is performed (the first distillation). After removing a majority of the light fraction, the macrolactone product is isolated from the
remaining reaction mixture by distillation (the second distillation). The macrolactone product may be further purified e.g., by flash column chromatography. Residue in the reaction vessel after distillation includes polymer (e.g., poly(11,15,15-trimethyl-1,8-dioxacyclopentadecan-9-one)). Product compositions and yields are determined e.g., by NMR.

[90] In some embodiments, citronellic acid is combined with ethylene glycol and methanesulfonic acid in an organic solvent (e.g., toluene) and heated, to 25 °C – 200 °C (e.g., to 25 °C, e.g., to 50 °C, e.g., to 75 °C, e.g., to 100 °C, e.g., to 110 °C, e.g., to 120 °C, e.g., to 130 °C, e.g., to 140 °C, e.g., to 150 °C, e.g., to 160 °C, e.g., to 180 °C, e.g., to 200 °C) for 0.5 – 10 hours (e.g., 0.5 hours, e.g., 1 hour, e.g., 2 hours, e.g., 3 hours, e.g., 4 hours, e.g., 5 hours, e.g., 6 hours, e.g., 8 hours, e.g., 10 hours), during which water is removed from the reaction, to perform the esterification step. The reaction is then cooled, to 25 °C – 100 °C (e.g., to 20-30 °C, e.g., to 30-40 °C, e.g., to 40-50 °C, e.g., to 50-60 °C, e.g., to 60-70 °C, e.g., to 70-80 °C, e.g., to 80-90 °C, e.g., to 90-100 °C) and left stirring, for 1 hour – 4 days (e.g., 1 hour, e.g., 6 hours, e.g., 12 hours, e.g., 1 day, e.g., 2 days, e.g., 3 days, e.g., 4 days), to perform the etherification step, before quenching the reaction with a basic aqueous solution (e.g., 10% Na₂CO₃) until the pH of the reaction mixture is slightly basic (e.g., pH = 8). A polar organic solvent (e.g., ethyl acetate) is added to reaction mixture and the phases are separated. The organic phase is washed with brine and then dried with a drying agent (e.g., Na₂SO₄). The drying agent is removed by filtration and the solvent is removed by evaporation, yielding a residue. An inorganic catalyst (e.g., MgO) and quenching agent (e.g., Na₂CO₃) are added to the residue, and fractional distillation is performed (first distillation). After removing a majority of the light fraction, the macrolactone product is removed from the remaining reaction mixture by distillation (second distillation). The macrolactone product may be further purified e.g., by flash column chromatography. Residue in the reaction vessel after distillation includes polymer (e.g., poly(7-(2-hydroxyethoxy)-3,7-dimethyloctanoic acid)). Product compositions and yields are determined e.g., by NMR.

[91] The process described herein can be applied using many different combinations of olefinic acids or esters and diols, resulting in a large variety of new compositions of matter. Further, the olefinic acids and esters can be etherified or hydroxylated at the
most highly substituted carbon of the olefin and used as a functional equivalent to the olefin. For example, Scheme 2 shows three functional equivalents for this process, where $R^1$, $R^3$, and $R^4$ are as defined in Formula III above.

**Scheme 2**

![Chemical structures](image)

such as

![Chemical structures](image)

such as

![Chemical structures](image)

such as

[92] Non-limiting examples of suitable olefinic acids and esters for the processes described herein include those depicted in Table 1 below, as well as their substituted and/or unsaturated analogs and functional equivalents. One of the ——— is a double bond and the other ——— is a single bond, and $R^3$ is as defined in Formula III above.

**Table 1**

<table>
<thead>
<tr>
<th><img src="image" alt="Chemical structures" /></th>
<th><img src="image" alt="Chemical structures" /></th>
<th><img src="image" alt="Chemical structures" /></th>
<th><img src="image" alt="Chemical structures" /></th>
<th><img src="image" alt="Chemical structures" /></th>
<th><img src="image" alt="Chemical structures" /></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Chemical structures" /></td>
<td><img src="image" alt="Chemical structures" /></td>
<td><img src="image" alt="Chemical structures" /></td>
<td><img src="image" alt="Chemical structures" /></td>
<td><img src="image" alt="Chemical structures" /></td>
<td><img src="image" alt="Chemical structures" /></td>
</tr>
</tbody>
</table>
Several of the molecules in Table 1, above, can be derived from renewable resources such as terpenes (e.g., citronellic acid and/or citronellenes) or unsaturated vegetable oil fatty acids. When obtaining these molecules from unsaturated fatty acids, metathesis of the fatty acids with a suitable olefin such as isobutylene or 2,3-dimethylbutene, or reductive ozonolysis followed by Wittig-type olefination, may yield suitable starting materials. Metathesis of fatty acids may also give rise to internal olefins that can then undergo olefin isomerization to produce compounds of the type described.
in Table 1. In general, the olefins and corresponding functional equivalents can also be made by adding organometallic species to esters, performing Wittig- or Homer-Wadsworth-Emmons-type olefinations of aldehydes, or by performing metathesis reactions on suitable olefin precursors.

[94] Suitable diols for the process described herein include, e.g., ethylene glycol, propylene glycol, erythritol, pentaerythritol, sorbitol, 1,3-propanediol, glycerol, 1,4-butanediol, 1,4-butanediol, 1,4- butanediol, 1,4- butanediol, 1,4- butanediol, 1,5-pentanediol, 1,6, hexanediol, 1,6- hexanediol, 1,6- hexanediol, 1,6-hexanediol, 1,7-heptanediol, 1,8-octanediol, 1,9-nonanediol, 1,10-decanediol, 1,11-dodecanediol, 1,12-dodecanediol, 1,13-tridecanediol, 1,14-tetradecanediol, 1,15-pentadecanediol, and 1,16-hexadecanediol, as well as their substituted, polymeric, and/or unsaturated analogs. Diols that are removed from the reaction mixtures described herein by distillation can be reused.

[95] The polymers obtained from this process may possess olefinic terminal groups, as described in Scheme 1 and as indicated in Formula II. These olefinic groups can be used to further grow the polymer and add additional functionality. Methods to prepare and grow olefinic polymers include free radical polymerization, metathesis polymerization, anionic polymerization, and/or cationic polymerization. Table 2 below includes representative polymers that can be obtained by the processes described herein, where \( n \) is as defined in Formula II above.

### Table 2

<table>
<thead>
<tr>
<th>COMPOUND NUMBER</th>
<th>STRUCTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>603</td>
<td><img src="image" alt="Structure 603" /></td>
</tr>
<tr>
<td>604</td>
<td><img src="image" alt="Structure 604" /></td>
</tr>
<tr>
<td>606</td>
<td><img src="image" alt="Structure 606" /></td>
</tr>
</tbody>
</table>
Representative macrocyclic compounds that can be obtained from the processes described herein are shown in Table 3.

**Table 3**

<table>
<thead>
<tr>
<th>COMPOUND NUMBER</th>
<th>STRUCTURE</th>
</tr>
</thead>
<tbody>
<tr>
<td>610</td>
<td><img src="image1" alt="Structure 610" /></td>
</tr>
<tr>
<td>703</td>
<td><img src="image2" alt="Structure 703" /></td>
</tr>
<tr>
<td>704</td>
<td><img src="image3" alt="Structure 704" /></td>
</tr>
<tr>
<td>706</td>
<td><img src="image4" alt="Structure 706" /></td>
</tr>
<tr>
<td>710</td>
<td><img src="image5" alt="Structure 710" /></td>
</tr>
<tr>
<td>101</td>
<td><img src="image6" alt="Structure 101" /></td>
</tr>
<tr>
<td>102</td>
<td><img src="image7" alt="Structure 102" /></td>
</tr>
<tr>
<td>COMPOUND NUMBER</td>
<td>STRUCTURE</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>103</td>
<td><img src="image1" alt="Structure 103" /></td>
</tr>
<tr>
<td>104</td>
<td><img src="image2" alt="Structure 104" /></td>
</tr>
<tr>
<td>105</td>
<td><img src="image3" alt="Structure 105" /></td>
</tr>
<tr>
<td>106</td>
<td><img src="image4" alt="Structure 106" /></td>
</tr>
<tr>
<td>107</td>
<td><img src="image5" alt="Structure 107" /></td>
</tr>
<tr>
<td>108</td>
<td><img src="image6" alt="Structure 108" /></td>
</tr>
<tr>
<td>109</td>
<td><img src="image7" alt="Structure 109" /></td>
</tr>
<tr>
<td>COMPOUND NUMBER</td>
<td>STRUCTURE</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>116</td>
<td><img src="image" alt="Structure 116" /></td>
</tr>
<tr>
<td>117</td>
<td><img src="image" alt="Structure 117" /></td>
</tr>
<tr>
<td>118</td>
<td><img src="image" alt="Structure 118" /></td>
</tr>
<tr>
<td>119</td>
<td><img src="image" alt="Structure 119" /></td>
</tr>
<tr>
<td>120</td>
<td><img src="image" alt="Structure 120" /></td>
</tr>
<tr>
<td>121</td>
<td><img src="image" alt="Structure 121" /></td>
</tr>
<tr>
<td>COMPOUND NUMBER</td>
<td>STRUCTURE</td>
</tr>
<tr>
<td>----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>122</td>
<td><img src="image" alt="Structure 122" /></td>
</tr>
<tr>
<td>123</td>
<td><img src="image" alt="Structure 123" /></td>
</tr>
<tr>
<td>124</td>
<td><img src="image" alt="Structure 124" /></td>
</tr>
<tr>
<td>125</td>
<td><img src="image" alt="Structure 125" /></td>
</tr>
<tr>
<td>205</td>
<td><img src="image" alt="Structure 205" /></td>
</tr>
<tr>
<td>206</td>
<td><img src="image" alt="Structure 206" /></td>
</tr>
<tr>
<td>COMPOUND NUMBER</td>
<td>STRUCTURE</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>207</td>
<td><img src="image1.png" alt="Image" /></td>
</tr>
<tr>
<td>210</td>
<td><img src="image2.png" alt="Image" /></td>
</tr>
<tr>
<td>214</td>
<td><img src="image3.png" alt="Image" /></td>
</tr>
<tr>
<td>216</td>
<td><img src="image4.png" alt="Image" /></td>
</tr>
<tr>
<td>219</td>
<td><img src="image5.png" alt="Image" /></td>
</tr>
<tr>
<td>220</td>
<td><img src="image6.png" alt="Image" /></td>
</tr>
<tr>
<td>COMPOUND NUMBER</td>
<td>STRUCTURE</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>223</td>
<td><img src="image" alt="Structure 223" /></td>
</tr>
<tr>
<td>305</td>
<td><img src="image" alt="Structure 305" /></td>
</tr>
<tr>
<td>306</td>
<td><img src="image" alt="Structure 306" /></td>
</tr>
<tr>
<td>310</td>
<td><img src="image" alt="Structure 310" /></td>
</tr>
<tr>
<td>314</td>
<td><img src="image" alt="Structure 314" /></td>
</tr>
<tr>
<td>320</td>
<td><img src="image" alt="Structure 320" /></td>
</tr>
<tr>
<td>COMPOUND NUMBER</td>
<td>STRUCTURE</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
</tr>
<tr>
<td>403</td>
<td><img src="image1" alt="Structure 403" /></td>
</tr>
<tr>
<td>404</td>
<td><img src="image2" alt="Structure 404" /></td>
</tr>
<tr>
<td>406</td>
<td><img src="image3" alt="Structure 406" /></td>
</tr>
<tr>
<td>410</td>
<td><img src="image4" alt="Structure 410" /></td>
</tr>
<tr>
<td>806</td>
<td><img src="image5" alt="Structure 806" /></td>
</tr>
<tr>
<td>810</td>
<td><img src="image6" alt="Structure 810" /></td>
</tr>
</tbody>
</table>
The macrocyclic compounds described herein can be used themselves, or as monomers for ring-opening polymerization. In some embodiments, an ester group oxygen atom of the macrocyclic compound of the application can be replaced with a nitrogen atom under high pressure with ammonia, thus allowing access to polyamide production (see e.g., Ritz, J., Fuchs, H., Kieczka, H. and Moran, W.C. 2011 Caprolactam. Ullmann's Encyclopedia of Industrial Chemistry). Scheme 3 below depicts a general synthesis route to convert macrocyclic ethers of the application to analogous macrocyclic amines and polyamines. The variables in Scheme 3 below, such as $R^1$, $R^2$, n, and Z, are as defined in Formulae I and II above.

Scheme 3
[98] The details of one or more embodiments of the application are set forth in the accompanying description below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. In the case of conflict, the present specification will control.

[99] Unless otherwise indicated, it is to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. In this specification and in the claims that follow, reference will be made to a number of terms, which shall be defined to have the definitions set forth below.

[100] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a reactant" includes not only a single reactant but also a combination or mixture of two or more different reactant, reference to "a substituent" includes a single substituent as well as two or more substituents, and the like.

[101] As used herein, the phrases "for example," "for instance," "such as," or "including" are meant to introduce examples that further clarify more general subject matter. These examples are provided only as an aid for understanding the disclosure, and are not meant to be limiting in any fashion. Furthermore as used herein, the terms "may," "optional," "optionally," or "may optionally" mean that the subsequently described circumstance may or may not occur, so that the description includes instances where the circumstance occurs and instances where it does not. For example, the phrase "optionally present" means that an object may or may not be present, and, thus, the description includes instances wherein the object is present and instances wherein the object is not present.

[102] As used herein, the phrase "having the formula" or "having the structure" is not intended to be limiting and is used in the same way that the term "comprising" is commonly used.

[103] "Isomerism" means compounds that have identical molecular formulae but
differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a “racemic mixture”.

[104] A carbon atom bonded to four nonidentical substituents is termed a “chiral center.”

[105] “Chiral isomer” means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed “diastereomeric mixture.” When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Int. Edit. 1966, 5, 385; errata 511; Cahn et al., Angew. Chem. 1966, 78, 413; Cahn and Ingold, J. Chem. Soc. 1951 (London), 612; Cahn et al., Experientia 1956, 12, 81; Cahn, J. Chem. Educ. 1964, 41, 116). In some formulae of the present application, one or more chiral centers are identified by an asterisk placed next to the chiral carbon. In other formulae, no chiral center is identified, but the chiral isomers are nonetheless covered by these formulae.

[106] “Geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds. These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.

[107] Some compounds of the present application can exist in a tautomeric form which is also intended to be encompassed within the scope of the present application. “Tautomers” refers to compounds whose structures differ markedly in arrangement of
atoms, but which exist in easy and rapid equilibrium. It is to be understood that the compounds of the application may be depicted as different tautomers. It should also be understood that when compounds have tautomeric forms, all tautomeric forms are intended to be within the scope of the application, and the naming of the compounds does not exclude any tautomeric form. Further, even though one tautomer may be described, the present application includes all tautomers of the present compounds.

[108] As used herein, the term “salt” can include acid addition salts including hydrochlorides, hydrobromides, phosphates, sulfates, hydrogen sulfates, alkylsulfonates, arylsulfonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, and tartrates; alkali metal cations such as Na⁺, K⁺, Li⁺, alkali earth metal salts such as Mg²⁺ or Ca²⁺, or organic amine salts, or organic phosphonium salts.

[109] The term "alkyl" as used herein refers to a monovalent or bivalent, branched or unbranched saturated hydrocarbon group typically although not necessarily containing 1 to about 12 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, octyl, and the like.

[110] The term "alkenyl" as used herein refers to a monovalent or bivalent, branched or unbranched, unsaturated hydrocarbon group typically although not necessarily containing 2 to about 12 carbon atoms and 1-10 carbon-carbon double bonds, such as ethylene, n-propylene, isopropylene, n-butylene, isobutylene, t-butylene, octylene, and the like.

[111] The term "alkynyl" as used herein refers to a monovalent or bivalent, branched or unbranched, unsaturated hydrocarbon group typically although not necessarily containing 2 to about 12 carbon atoms and 1-6 carbon-carbon triple bonds, such as ethyne, propyne, butyne, pentyne, hexyne, heptyne, octyne, and the like.

[112] By "substituted" as in "substituted alkyl," "substituted alkenyl," “substituted alkynyl,” and the like, it is meant that in the alkyl, alkenyl, alkynyl, or other moiety, at least one hydrogen atom bound to a carbon atom is replaced with one or more non-hydrogen substituents, e.g., by a functional group.

[113] Examples of functional groups include, without limitation: halo, hydroxyl, sulphydryl, C₁-C₂₄ alkoxy, C₂-C₂₄ alkenyloxy, C₂-C₂₄ alkynyloxy, C₅-C₂₀ aryloxy, acyl (including C₂-C₂₄ alkylcarbonyl (-CO-alkyl) and C₆-C₂₀ arylcarbonyl (-CO-aryl)), acyloxy
(-O-acyl), C₂-C₂₄ alkoxy carbonyl (-CO-O-alkyl), C₆-C₂₀ aryloxy carbonyl (-CO-O-aryl), halocarbonyl (-CO-X where X is halo), C₂-C₂₄ alkylicarbonato (-O-(CO-O)-alkyl), C₆-C₂₀ arylcarbonato (-O-(CO-O)-aryl), carboxy (-COOH), carboxylato (-COO⁻), carbamoyl (-CO-NH₂), mono-substituted C₁-C₂₄ alkyl carbamoyl (-CO-NH(C₁-C₂₄ alkyl)), di-substituted alkyl carbamoyl (-CO)-N(C₁-C₂₄ alkyl)₂, mono-substituted aryl carbamoyl (-CO-NH-C₅-C₂₀ aryl), thiocarbamoyl (-CS-NH₂), carbamido (-NH(CO)-NH₂), cyano (-C≡N), isocnyano (-N≡C⁻), cyanato (-O-C≡N), isocyanato (-O-N≡C⁻), isothiocyanato (-S-C≡N), azido (-N=N≡N⁻), formyl (-CO-H), thioformyl (-CS-H), amino (-NH₂), mono- and di-(C₁-C₂₄ alkyl)-substituted amino, mono- and di-(C₅-C₂₀ aryl)-substituted amino, C₂-C₂₄ alkylamido (-NH-(CO)-alkyl), C₅-C₂₀ arylamido (-NH-(CO)-aryl), imino (-CR=NH where R = hydrogen, C₁-C₂₄ alkyl, C₅-C₂₀ aryl, C₆-C₂₀ alkaryl, C₆-C₂₀ aralkyl, etc.), alkylimino (-CR=N(alkyl), where R = hydrogen, alkyl, aryl, alkaryl, etc.), arylimino (-CR=N(aryl), where R = hydrogen, alkyl, aryl, alkaryl, etc.), nitro (-NO₂), nitroso (-NO), sulfo (-SO₂-OH), sulfonato (-SO₂-O⁻), C₁-C₂₄ alkylsulfanyli (-S-alkyl; also termed "alkylthio"), arylsulfanyl (-S-aryl; also termed "aryltio"), C₁-C₂₄ alkylsulfinyl (-SO₁-alkyl), C₅-C₂₀ arylsulfinyl (-SO₁-aryl), C₁-C₂₄ alkylsulfonyl (-SO₂-alkyl), C₅-C₂₀ arylsulfonyl (-SO₂-aryl), phosphono (-P(O)(OH)₂), phosphonato (-P(O)(O⁻)₂), phosphinato (-P(O)(O⁻)), phospho (-PO₂⁻), phosphino (-PH₂), mono- and di-(C₁-C₂₄ alkyl)-substituted phosphino, mono- and di-(C₅-C₂₀ aryl)-substituted phosphino; and the hydrocarbyl moieties such as C₁-C₂₄ alkyl (including C₁-C₁₈ alkyl, further including C₁-C₁₂ alkyl, and further including C₁-C₆ alkyl), C₂-C₂₄ alkenyl (including C₂-C₁₈ alkenyl, further including C₂-C₁₂ alkenyl, and further including C₂-C₆ alkenyl), C₆-C₂₄ alkynyl (including C₂-C₁₈ alkynyl, further including C₂-C₁₂ alkynyl, and further including C₂-C₆ alkynyl), C₆-C₂₄ alkenynyl (including C₂-C₁₈ alkenynyl, further including C₂-C₁₂ alkenynyl, and further including C₂-C₆ alkenynyl), C₅-C₃₀ aryl (including C₅-C₂₀ aryl, and further including C₅-C₁₂ aryl), and C₆-C₃₀ aralkyl (including C₆-C₂₀ aralkyl, and further including C₆-C₁₂ aralkyl). In addition, the aforementioned functional groups may, if a particular group permits, be further substituted with one or more additional functional groups or with one or more hydrocarbyl moieties such as those specifically enumerated above.

[114] In the present specification, the structural formula of the compound represents a certain isomer for convenience in some cases, but the present application includes all isomers, such as geometrical isomers, optical isomers based on an
asymmetrical carbon, stereoisomers, tautomers, and the like. In addition, a crystal polymorphism may be present for the compounds represented by the formula. It is noted that any crystal form, crystal form mixture, or anhydride or hydrate thereof is included in the scope of the present application.

[115] All percentages used herein, unless otherwise indicated, are by volume.

[116] All ratios used herein, unless otherwise indicated, are by molarity.

Examples

Example 1: Synthesis of 3,7,7-trimethyl-1,8-dioxacyclotetradecan-2-one and its polymeric precursor

[117] A mixture of 2,6-dimethyl-6-methoxyheptanoic acid (100 g, 0.53 mol), 1,6-hexanediol (125.5 g), methanesulfonic acid (10 g) and toluene (100 ml) in a 500 mL round bottom flask equipped with a Dean-Stark apparatus was heated at 120 °C for 4 hours, removing water formed in the Dean-Stark apparatus during the process. The reaction was cooled to 50-60 °C and additional 1,6-hexanediol (36 g) was added to the mixture. The reaction was then kept stirring at this temperature for 2 days before quenching the reaction with aqueous Na₂CO₃ (10% (w/v)) at room temperature (until pH = 8). Ethyl acetate (100 ml) was added to the mixture and the phases were separated. The organic phase was washed with brine (150 ml) and then dried with Na₂SO₄. The Na₂SO₄ was filtered out and solvent was removed from the organic phase by evaporation, resulting in a red liquid residue (167 g). MgO (4 g) and Na₂CO₃ (4 g) were added to an aliquot of the residue (80 g) and fractional distillation was performed by heating the mixture from 25 to 250 °C under vacuum. After removing most of the light fraction at 1.0-1.6 mbar, the final fraction containing the macrolactone product was
distilled from the remaining reaction mixture at 200-260 °C under 0.1-0.5 mbar vacuum. Purification of the final distillation fraction by flash column chromatography gave 2 g of macrolactone product (silica gel, 2-7.5% ethyl acetate/heptane). Residue in the reaction vessel after distillation (28 g) comprised poly(6-(6-hydroxyhexyl)oxy)-2,6-dimethylheptanoic acid), MgO, and Na₂CO₃. NMR spectra for the macrolactone and polymer products are described below.

3,7,7-trimethyl-1,8-dioxacyclotetradecan-2-one

[118] ¹H NMR (CDCl₃, 400 MHz) δ 1.12 (s, 3H, -CH₃), 1.13 (s, 3H, -CH₃), 1.15 (d, J = 7.2 Hz, 3H, -CH₃), 1.18-1.28 (m, 1H, -CH-), 1.34-1.75 (m, 13H, -CH₂-), 2.49-2.54 (m, 1H, -CH-), 3.24-3.32 (m, 2H, -CH₂O-), 4.05-4.11 (m, 1H, -CH₂O-), 4.13-4.19 (m, 1H, -CH₂O-). ¹³C NMR (100 MHz, CDCl₃) δ 17.4, 20.5, 23.7, 24.1, 26.5, 26.6, 28.2, 29.1, 34.8, 37.8, 40.4, 58.3, 63.1, 73.5, 176.4;

poly(6-(6-hydroxyhexyl)oxy)-2,6-dimethylheptanoic acid, or alternatively, poly(3,7,7-trimethyl-1,8-dioxacyclotetradecan-2-one)

[119] ¹H NMR (CDCl₃, 400 MHz) δ 1.10 (s, 6H, -CH₃), 1.13 (d, J = 6.8 Hz, 3H, -CH₃), 1.25-1.67 (m, 14H, -CH₂-), 2.39-2.44 (m, 1H, -CH-), 3.26 (t, 2H, J = 6.4 Hz, -CH₂O-), 4.04 (t, 2H, J = 6.4 Hz, -CH₂O-).

Example 2: Synthesis of 11,15,15-trimethyl-1,8-dioxacyclopentadecan-9-one and its polymeric precursor
A mixture of citronellic acid (50 g, 0.29 mol), 1,6-hexanediol (69 g), methanesulfonic acid (5 g) and toluene (100 ml) in 500 mL was heated in a round bottom flask equipped with a Dean-Stark apparatus at 120 °C for 4 hours, removing the water formed in the Dean-Stark apparatus during the process. The reaction was cooled to 50-60 °C and additional 1,6-hexanediol (34.5 g) was added to the mixture. The reaction was then kept stirring at this temperature for 2 days before quenching the reaction with aqueous Na₂CO₃ (10% (w/v)) at room temperature (until pH = 8). Ethyl acetate (100 ml) was added to the mixture and the phases were separated. The organic phase was washed with brine (150 ml) and then dried with Na₂SO₄. The Na₂SO₄ was filtered out and solvent was removed from the organic phase by evaporation, resulting in a red liquid residue (107 g). MgO (5 g) and Na₂CO₃ (5 g) were added to the residue and fractional distillation was performed by heating the mixture from 25 to 260 °C under vacuum. After removing most of the light fraction at 0.5-1.0 mbar, the final fraction containing the macrolactone product was distilled from the remaining reaction mixture at 200-270 °C under 0.3-0.5 mbar vacuum. Purification of the final distillation fraction by flash column chromatography gave 3.2 g of macrolactone product (silica gel, 2-7.5% ethyl acetate/heptane). Residue in the reaction vessel after distillation (20 g) comprised poly(11,15,15-trimethyl-1,8-dioxacyclopentadecan-9-one), MgO, and Na₂CO₃. NMR spectra for the macrolactone and polymer products are described below.
11,15,15-trimethyl-1,8-dioxacyclopentadecan-9-one

[121] \(^1\)H NMR (CDCl\(_3\), 500 MHz) \(\delta\) 0.98 (d, \(J = 7.5\) Hz 3H, -CH\(_3\)), 1.12 (s, 3H, -CH\(_3\)), 1.13 (s, 3H, -CH\(_3\)), 1.23-1.71 (m, 16H, -CH\(_2\)-), 2.02-2.06 (m, 1H, -CH-), 2.12-2.17 (m, 1H, -CH\(_2\)-), 2.29-2.35 (m, 1H, -CH\(_2\)-), 3.27-3.30 (m, 2H, -CH\(_2\)O-), 4.05-4.09 (m, 1H, -CH\(_2\)O-), 4.13-4.17 (m, 1H, -CH\(_2\)O-).

poly(11,15,15-trimethyl-1,8-dioxacyclopentadecan-9-one)

[122] \(^1\)H NMR (CDCl\(_3\), 400 MHz) \(\delta\) 0.92 (d, \(J = 6.4\) Hz 3H, -CH\(_3\)), 1.12 (s, 6H, -CH\(_3\)), 1.22-1.67 (m, 14H, -CH\(_2\)-), 1.93-1.93 (m, 1H, -CH-), 2.06-2.12 (m, 1H, -CH\(_2\)-), 2.26-2.31 (m, 1H, -CH\(_2\)-), 3.27 (t, \(J = 6.8\) Hz, 2H, -CH\(_2\)O-), 4.05 (m, \(J = 6.8\) Hz, 2H, -CH\(_2\)O-).
Example 3: Synthesis of 8,12,12-trimethyl-1,5-dioxacyclododecan-6-one and its polymeric precursor.

A mixture of citronelic acid (47.3 g, 0.278 mol), 1,3-propanediol (84.6 g, 1.112 mol), and methanesulfonic acid (4.73 g) was heated to 120 °C in a 500 mL round bottom flask equipped with distillation head for 5 hours, during which water was removed from the reaction via the distillation head. The reaction was then cooled to room temperature and left stirring for 3 days, at which time the reaction was quenched with aqueous NaCO₃ (10% (w/v)) at room temperature (until pH = 8). Ethyl acetate (200 ml x 2) was added to the reaction and the phases were separated. The organic phase (ethyl acetate solution) was washed with brine (150 ml), and dried with Na₂SO₄, which was subsequently removed by filtration. Solvent was then removed from the organic phase by evaporation, resulting in a red liquid residue (60 g). MgO (3 g) and NaCO₃ (3 g) were added to the residue and fractional distillation was performed by heating the mixture from 25 to 250 °C under 1.0-1.6 mbar vacuum. After removing a majority of light fraction at 1.0-1.6 mbar, the final fraction containing the macrolactone product was distilled from the remaining reaction mixture at 200-250 °C under 0.4-1.0 mbar vacuum. Purification of the final distillation fraction by flash column chromatography gave 0.84 g of macrolactone product (silica gel, 5-7.5% ethyl acetate/heptane). Residue in the reaction vessel after distillation (20 g) comprised poly(7-(3-hydroxypropoxy)-3,7-
dimethyloctanoic acid) (Figure 2), MgO, and Na₂CO₃. NMR spectra for the macrolactone and polymer products are described below.

8,12,12-trimethyl-1,5-dioxacyclododecan-6-one

Figure 1 depicts the ¹H NMR (400 MHz) spectrum of 8,12,12-trimethyl-1,5-dioxacyclododecan-6-one in CDCl₃. Chemical shift values (in ppm) for peaks in the spectrum are: δ 0.96 (d, J = 7.2 Hz, 3H, -CH₃), 1.09 (s, 3H, -CH₃), 1.11 (s, 3H, -CH₃), 1.14-1.40 (m, 5H, -CH₂-), 1.68-1.75 (m, 1H, -CH-), 1.85-1.97 (m, 3H, -CH₂-), 2.08-2.13 (m, 1H, -CH-), 2.41 (dd, J = 12.8 Hz, J = 2.4 Hz, 1H, -CH₂-), 3.34-3.39 (m, 1H, -CH₂O-), 3.45-3.50 (m, 1H, -CH₂O-), 4.07-4.13 (m, 1H, -CH₂O-), 4.20-4.25 (m, 1H, -CH₂O-).

poly(7-(3-hydroxypropoxy)-3,7-dimethyloctanoic acid), or alternatively, poly(8,12,12-trimethyl-1,5-dioxacyclododecan-6-one)

Figure 2 depicts the ¹H NMR (400 MHz) spectrum of poly(7-(3-hydroxypropoxy)-3,7-dimethyloctanoic acid) in CDCl₃. Chemical shift values (in ppm) for peaks in the spectrum are: δ 0.92 (d, J = 6.4 Hz, 3H, -CH₃), 1.10-1.41 (m, 11H, -CH₃, -CH₂-), 1.78-1.84 (m, 2H, -CH₂-), 1.93-1.97 (m, 2H, -CH-), 2.05-2.12 (m, 1H, -CH-), 2.25-2.35 (1, 2H, -CH-), 3.35 (t, 2H, J = 6.4 Hz, -CH₂O-), 4.13 (t, 2H, J = 6.4 Hz, -CH₂O-).
Example 4: Synthesis of 7,11,11-trimethyl-1,4-dioxacycloundecan-5-one and its polymeric precursor.

[126] A mixture of citronellic acid (40 g, 0.235 mol), ethylene glycol (72.9 g, 1.175 mol), and methanesulfonic acid (2 g) was heated to 120 °C in a 500 mL round bottom flask equipped with distillation head for 5 hours, during which water was removed from the reaction via the distillation head. The reaction was then cooled to room temperature and left stirring for 3 days, at which time the reaction was quenched with aqueous NaCO₃ (10% (w/v)) at room temperature (until pH = 8). Ethyl acetate (150mL + 50mL) was added to the reaction and the phases were separated. The organic phase (ethyl acetate solution) was washed with brine (150 ml), and dried with Na₂SO₄, which was subsequently removed by filtration. Solvent was then removed from the organic phase by evaporation, resulting in a red liquid residue (60 g). MgO (3 g) and NaCO₃ (3 g) were added to the residue and fractional distillation was performed by heating the mixture from 25 to 250 °C under 0.4-1.0 mbar vacuum. After removing a majority of light fraction at 0.4-1.0 mbar, the final fraction containing the macrolactone product was distilled from the reaction at 250 °C under 0.4-1.0 mbar vacuum for 8 hours. Purification of the final distillation fraction by flash column chromatography gave 1.0 g of macrolactone product (silica gel, 5-7.5% ethyl acetate/heptane). Residue in the reaction vessel after distillation (15 g) comprised poly(7-(2-hydroxyethoxy)-3,7-
dimethyloctanoic acid) (Figure 4), MgO, and Na₂CO₃. NMR spectra for the macrolactone and polymer products are described below.

![Chemical structure of 7,11,11-trimethyl-1,4-dioxacycloundecan-5-one]

7,11,11-trimethyl-1,4-dioxacycloundecan-5-one

[127] Figure 3 depicts the ¹H NMR (300 MHz) spectrum of 7,11,11-trimethyl-1,4-dioxacycloundecan-5-one in CDCl₃. Chemical shift values (in ppm) for peaks in the spectrum are: δ 0.96 (d, J = 5.4 Hz, 3H, -CH₃), 1.10 (s, 3H, -CH₃), 1.15 (s, 3H, -CH₃), 1.27-1.64 (m, 5H, -CH₂-), 1.72-1.82 (m, 1H, -CH-), 1.99-2.07 (m, 1H, -CH₂-), 2.22-2.38 (m, 2H, -CH-), 3.52 (dt, J = 12.6 Hz, J = 1.8 Hz, 1H, -CH₂O-), 3.67-3.75 (m, 1H, -CH₂O-), 3.84 (td, J = 11.7 Hz, J = 1.8 Hz, 1H, -CH₂O-), 4.63-4.71 (m, 1H, -CH₂O-).

![Chemical structure of poly(7-(2-hydroxyethoxy)-3,7-dimethyloctanoic acid)]

poly(7-(2-hydroxyethoxy)-3,7-dimethyloctanoic acid), or alternatively, poly(7,11,11-trimethyl-1,4-dioxacycloundecan-5-one)

[128] Figure 4 depicts the ¹H NMR (300 MHz) spectrum of poly(7-(2-hydroxyethoxy)-3,7-dimethyloctanoic acid) in CDCl₃. Chemical shift values (in ppm) for peaks in the spectrum are: δ 0.92 (d, J = 6.6 Hz, 3H, -CH₃), 1.13-1.40 (m, 11H, -CH₃, -CH₂-), 1.86-1.95 (m, 2H, -CH₂-), 2.08-2.15 (m, 1H, -CH-), 2.28-2.36 (1, 1H, -CH-), 3.49 (t, 2H, J = 5.1 Hz, -CH₂O-), 4.15 (t, 2H, J = 5.1 Hz, -CH₂O-).

**INCORPORATION BY REFERENCE**

[129] The entire disclosure of each of the patent documents and scientific articles referred to herein is incorporated by reference for all purposes.
EQUIVALENTS

[130] The application can be embodied in other specific forms without departing from the spirit or essential characteristics thereof. The foregoing embodiments are therefore to be considered in all respects illustrative rather than limiting on the application described herein. Scope of the application is thus indicated by the appended claims rather than by the foregoing description, and all changes that come within the meaning and range of equivalency of the claims are intended to be embraced therein.
What is claimed:

1. A compound according to Formula I or Formula II:

   ![Formula I](image)

   **Formula I, or**

   ![Formula II](image)

   or a salt thereof, wherein,

   - $R^1$ is a bond, optionally substituted C$_{1-12}$ alkyl, optionally substituted C$_{2-12}$ alkenyl, or optionally substituted C$_{2-12}$ alkynyl;
   - $R^2$ is optionally substituted C$_{1-12}$ alkyl, optionally substituted C$_{2-12}$ alkenyl, or optionally substituted C$_{2-12}$ alkynyl;
   - $X$ is O or NR$^a$;
   - $R^x$ is hydrogen or optionally substituted C$_{1-12}$ alkyl;
   - $Z$ is hydrogen or \(\equiv\) ;
   - one of the \(\equiv\) is a double bond and the other \(\equiv\) is a single bond;
   - $m$ is an integer between 1 and 10; and
   - $n$ is an integer between 1 and 100,000.

2. The compound of claim 1 according to Formula I.

3. The compound of claim 1 according to Formula II.
4. The compound of claim 2, wherein the number of atoms comprising the ring structure is between 10 and 30.

5. The compound of claim 2, wherein the number of atoms comprising the ring structure is between 13 and 19.

6. The compound of any one of claims 1-5, wherein X is O.

7. The compound of any one of claims 1-5, wherein X is NH.

8. The compound of any one of claims 1-7, wherein Z is hydrogen.

9. The compound of any one of claims 1-7, wherein Z is [structure diagram].

10. The compound of any one of claims 1-9, wherein R¹ is optionally substituted linear C₁⁻C₁₂ alkyl or branched C₃⁻C₁₂ alkyl.

11. The compound of any one of claims 1-9, wherein R¹ is unsubstituted linear C₁⁻C₁₂ alkyl or branched C₃⁻C₁₂ alkyl.

12. The compound of any one of claims 1-9, wherein R¹ is optionally substituted linear C₂⁻C₁₂ alkenyl or branched C₃⁻C₁₂ alkenyl.

13. The compound of any one of claims 1-9, wherein R¹ is unsubstituted linear C₂⁻C₁₂ alkenyl or branched C₃⁻C₁₂ alkenyl.
14. The compound of any one of claims 1-13, wherein R² is optionally substituted linear C₁-C₁₂ alkyl or branched C₃-C₁₂ alkyl.

15. The compound of any one of claims 1-13, wherein R² is linear C₁-C₁₂ alkyl or branched C₃-C₁₂ alkyl substituted with one or more hydroxyl groups.

16. The compound of any one of claims 1-13, wherein R² is unsubstituted linear C₁-C₁₂ alkyl or branched C₃-C₁₂ alkyl.

17. The compound of any one of claims 1-13, wherein R² is optionally substituted linear C₂-C₁₂ alkenyl or branched C₃-C₁₂ alkenyl.

18. The compound of any one of claims 1-13, wherein R² is unsubstituted linear C₂-C₁₂ alkenyl or branched C₃-C₁₂ alkenyl.

19. The compound of any one of claims 1-13, wherein R² is optionally substituted linear C₂-C₁₂ alkynyl or branched C₄-C₁₂ alkynyl.

20. The compound of any one of claims 1-13, wherein R² is unsubstituted linear C₂-C₁₂ alkynyl or branched C₄-C₁₂ alkynyl.

21. The compound of claim 1, selected from those listed in Table 2 and salts thereof.

22. The compound of claim 1, selected from those listed in Table 3 and salts thereof.

23. A method of producing a compound of claim 1, or a salt thereof, comprising reacting a compound of Formula III or Formula IV:

\[
\text{Formula III, or}
\]
with a compound of Formula V:

\[
\begin{align*}
&\text{HO} \\
&\text{R}^2 - \text{OH}
\end{align*}
\]

\text{Formula V,}

to obtain a reaction mixture comprising a compound of Formula I or Formula II, a salt thereof, or a combination thereof:

\[
\begin{align*}
\text{O} \\
\text{R}^1 \text{C} & \text{C} \\
\text{O} & \text{R}^2 \\
\end{align*}
\]

\text{Formula I, or}

\[
\begin{align*}
\text{Z} & \text{X} \text{R}^2 \text{O} \\
\text{R}^1 & \text{C} \text{C} \\
\text{Z} & \text{X} \text{R}^2 \text{O} \\
\end{align*}
\]

\text{Formula II,}

wherein,

- R\(^1\) is a bond, optionally substituted C\(_{1-12}\) alkyl, optionally substituted C\(_{2-12}\) alkenyl, or optionally substituted C\(_{2-12}\) alkynyl;
- R\(^2\) is optionally substituted C\(_{1-12}\) alkyl, optionally substituted C\(_{2-12}\) alkenyl, or optionally substituted C\(_{2-12}\) alkynyl;
- R\(^3\) is hydrogen, optionally substituted C\(_{1-12}\) alkyl, optionally substituted C\(_{2-12}\) alkenyl, or optionally substituted C\(_{2-12}\) alkynyl;
- R\(^4\) is hydrogen, optionally substituted C\(_{1-12}\) alkyl, optionally substituted C\(_{2-12}\) alkenyl, or optionally substituted C\(_{2-12}\) alkynyl;
- X is O or NR\(^x\);
R\(^x\) is hydrogen or optionally substituted C\(_1\)-C\(_{12}\) alkyl;

\[
\begin{align*}
\text{Z is hydrogen or } & \quad \text{; } \\
\text{one of the } & \quad \text{ is a double bond and the other } \quad \text{ is a single bond; } \\
m & \text{ is an integer between 1 and 10; and } \\
n & \text{ is an integer between 1 and 100,000.}
\end{align*}
\]

24. The method of claim 23, wherein the reaction of the compound of Formula III or Formula IV with the compound of Formula V comprises an esterification step, an etherification step, a first distillation step, and a second distillation step.

25. The method of claim 23 or 24, further comprising an amidation step, wherein a compound of Formula I, wherein X is O, reacts with NH\(_3\) under an elevated pressure to obtain a corresponding compound of Formula I, wherein X is NH.

26. The method of claim 24, wherein the ratio of the compound of Formula III or Formula IV to the compound of Formula V is 2 to 1 or greater.

27. The method of any one of claims 24-26, wherein the esterification step is performed at a first temperature that is greater than room temperature.

28. The method of claim 27, wherein the first temperature is about 125 °C.

29. The method of any one of claims 24-28, wherein the esterification step is performed at a first pH value that is less than or equal to 7.

30. The method of any one of claims 27-29, wherein the etherification step is performed at a second temperature that is lower than the first temperature.
31. The method of claim 30, wherein the second temperature is about 65 °C.

32. The method of claim 30, wherein the second temperature is about 25 °C.

33. The method of any one of claims 29-32, wherein the etherification step is performed at a second pH value that is greater than or equal to the first pH value.

34. The method of any one of claims 24-33, wherein the etherification step is quenched with a base.

35. The method of any one of claims 24-34, wherein the etherification step is performed for about 48 hours or less.

36. The method of any one of claims 24-35, wherein each of the first and second distillation steps is independently performed at a third temperature that is between 25 °C and 260 °C.

37. The method of any one of claims 24-36, wherein each of the first and second distillation steps is independently performed at a pressure between 0.1 and 1.6 mbar.

38. The method of any one of claims 24-37, wherein R³ is hydrogen.

39. The method of any one of claims 24-38, wherein the compound of Formula III or Formula IV is selected from Table 1.

40. The method of any one of claims 24-38, wherein the compound of Formula III is citronellic acid.

41. The method of any one of claims 24-38, wherein the compound of Formula IV is 2,6-dimethyl-6-methoxyheptanoic acid.
42. The method of any one of claims 24-38, wherein the compound of Formula V is 1,6-hexanediol.

43. The method of any one of claims 24-38, wherein the compound of Formula V is 1,3-propanediol.

44. The method of any one of claims 24-38, wherein the compound of Formula V is ethylene glycol.
Figure 1.
poly(7-(3-hydroxypropoxy)-3,7-dimethyloctanoic acid) or poly(8,12,12-trimethyl-1,5-dioxacyclododecan-6-one)

Figure 2.
7,11,11-trimethyl-1,4-dioxacyclododecan-5-one
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
IPC(8) - C07D 321/00 (2015.01)
CPC - C07D 321/00
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC(8): C07D 321/00 (2015.01)
CPC: C07D 321/00
USPC: 549/263, 267

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
PATSEARCH (US, EP, WO, JP, DE, GB, CN, FR, KR, ES, AU, IN, CA, INPADOC Data); ProQuest; Google Scholar; IP.com; EBSCO; SureChEMBL; KEYWORDS: macrocyclic, lactone, cyclic ester, ether link, macrocyclic ether lactone, method, form, product, process, hydroxy ether acid, catalys, esteri, macrocyclic lactone, carboxylic acid ester, diol, hexanediol, cyclic ether, olefinic acid.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>US 4,218,376 A (HARRIS, EG et al.) 19 August 1980; column 3, lines 36-40, 62-65; column 4, lines 40-51</td>
<td>1-2, 4-5, 6/1-2, 6/4-5, 7/1-2, 7/4-5, 22-24, 25/23-24, 26</td>
</tr>
<tr>
<td>A</td>
<td>US 5,264,547 A (YAMAGUCHI, A et al.) 23 November 1993; column 3, lines 11-12, 35-40, 55-56; column 4, lines 32-34, 37-47</td>
<td>1-5, 6/1-5, 7/1-5, 21-24, 25/23-24, 26</td>
</tr>
<tr>
<td>A</td>
<td>US 3,980,697 A (EL-CHAHAWI, M et al.) 14 September 1976; column 3, lines 21-30; column 6, lines 5-6</td>
<td>1, 3, 6/3, 7/3, 21</td>
</tr>
</tbody>
</table>

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:
- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier application or patent but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "X" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "A" document member of the same patent family

Date of the actual completion of the international search
06 July 2015 (06.07.2015)

Date of mailing of the international search report
31 JUL 2015

Name and mailing address of the ISA/
Mail Stop PCT, Attn: ISA/US, Commissioner for Patents
P.O. Box 1450, Alexandria, Virginia 22313-1450
Facsimile No. 571-272-8300

Authorized officer
Shane Thomas
PCT Helpdesk: 571-272-4300
PCT GSP: 571-272-7774

Form PCT/ISA/210 (second sheet) (January 2015)
# INTERNATIONAL SEARCH REPORT

## Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [ ] Claims Nos., because they relate to subject matter not required to be searched by this Authority, namely:

2. [ ] Claims Nos., because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. [x] Claims Nos. 8-20 and 27-44, because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.:

### Remark on Protest

[ ] The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.

[ ] The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.

[ ] No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (2)) (January 2015)